2012-12012. National Institute of Diabetes and Digestive and Kidney Disorders; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.) notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for type 1 diabetes. The outcome of the evaluation will be a decision whether NIDDK should support the request and make available contract resources for development of the potential therapeutic to improve the treatment or prevent the development of type 1 diabetes and its complications. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Type 1 Diabetes—Rapid Access to Intervention Development Special Emphasis Panel; National Institute of Diabetes and Digestive and Kidney Diseases.

Date: June 21, 2012.

Time: 3:00 p.m.-5:00 p.m.

Agenda: To evaluate requests for preclinical development resources for potential new therapeutics for type 1 diabetes and its complications.

Place: 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Dr. Aaron Pawlyk, Program Director for Pharmacogenomics and Drug Discovery, National Institute of Diabetes and Digestive and Kidney Diseases, Building 2DEM, Room 788B, 6707 Democracy Boulevard, Bethesda, MD 20892, Tel: [phone], Fax: [phone], Email: [e-mail].

Name of Committee: Type 1 Diabetes—Rapid Access to Intervention Development Special Emphasis Panel; National Institute of Diabetes and Digestive and Kidney Diseases.

Date: June 22, 2012.

Time: 10:00 p.m.-12:00 p.m.

Agenda: To evaluate requests for preclinical development resources for potential new therapeutics for type 1 diabetes and its complications.

Place: 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Dr. Aaron Pawlyk, Program Director for Pharmacogenomics and Drug Discovery, National Institute of Diabetes and Digestive and Kidney Diseases, Building 2DEM, Room 788B, 6707 Democracy Boulevard, Bethesda, MD 20892, Tel: [phone], Fax: [phone], Email: [e-mail].

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 98.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: May 11, 2012.

Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.